Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board
Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China.
You may also be interested in...
The Japan-headquartered drugmaker says there is a need for affordable oral treatment options on top of currently available lipid-lowering therapies and the two drugs it licensed from Esperion can meet that need.
The company hopes to sidestep payer restrictions and patient abandonment by launching the cholesterol-lowering medicine at a palatable price point in line with where branded statins were before patent expiry.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.